Daiichi Sankyo subsidiary Luitpold Pharmaceuticals has acquired Roxro Pharma, which specializes in intranasal delivery of analgesics. Roxro’s lead product is Sprix ketorolac tromethamine nasal spray for short-term pain management. Sprix received FDA approval in May 2010 but has not yet been marketed. Read the company’s press release.
Luitpold acquires Roxro and its Sprix nasal spray
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
